Evaluation of the drug-drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach

Abstract Brigatinib is an oral anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK‐positive metastatic non‐small cell lung cancer. In vitro studies indicated that brigatinib is primarily metabolized by CYP2C8 and CYP3A4 and inhibits P‐gp, BCRP, OCT1, MATE1, and MATE2K. Clini...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Michael J. Hanley (Autor), Karen Rowland Yeo (Autor), Meera Tugnait (Autor), Shinji Iwasaki (Autor), Narayana Narasimhan (Autor), Pingkuan Zhang (Autor), Karthik Venkatakrishnan (Autor), Neeraj Gupta (Autor)
Formato: Libro
Publicado: Wiley, 2024-04-01T00:00:00Z.
Materias:
Acceso en línea:Connect to this object online.
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

Connect to this object online.

3rd Floor Main Library

Detalle de Existencias desde 3rd Floor Main Library
Número de Clasificación: A1234.567
Copia 1 Disponible